Skip to main content

Is it true that PMX-DHP can improve lung oxygenation?

Polymyxin B immobilized fiber (PMX-R; Toray industries, Inc) has been developed in Japan for direct removal of endotoxin (PMX-DHP). PMX-DHP is used for treatment of patients with sepsis and septic shock primarily caused by Gram-negative infections, and its effectiveness of hemodynamic changes has been evaluated. In 119 cases (62 ± 16 years old, 82 men and 37 women) treated with PMX-DHP, changes in pulmonary oxygenation before and after PMX-DHP were examined, using PaO2/FiO2 as an oxygenation indicator, separately according to the outcome (80 survivors and 39 who died). Improvement of PaO2/FiO2 was identified in 64% of all cases. In the survival group, there appeared to be a trend for PaO2/FiO2 improvement as blood pressure increased. In the non-survival group, however, no improvement of PaO2/FiO2 was obtained, regardless of an increase of blood pressure. There was no significant correlation between PaO2/FiO2 and the rate of change in endotoxin levels, TNF-α, and IL-6. Granulocyte elastase increased significantly after PMX-DHP treatment in both groups. In the survival group, PaO2/FiO2 appeared to increase as macrophage inflammatory protein (MIP-1) 1-α decreased, suggesting the possibility that changes in MIP-1-α influenced PaO2/FiO2. As the mechanism for the improvement of pulmonary oxygenation by PMX-DHP has been shown clearly, it remains to be examined further.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ikeda, T., Ikeda, K., Suzuki, H. et al. Is it true that PMX-DHP can improve lung oxygenation?. Crit Care 7, P217 (2003).

Download citation

  • Published:

  • DOI:


  • Public Health
  • Blood Pressure
  • Septic Shock
  • Emergency Medicine
  • Survival Group